Table 4.
Comparison of baseline characteristics of study participants in the four study groups
| Ubiquinol + D-Ribose |
D-Ribose |
Ubiquinol |
Placebo |
|||||
|---|---|---|---|---|---|---|---|---|
| Completers | Noncompleters | Completers | Noncompleters | Completers | Noncompleters | Completers | Noncompleters | |
| Total per group, N | 33 | 5 | 33 | 4 | 35 | 4 | 38 | 1 |
| Baseline KCCQ Clinical Summary Score, mean (SD) | 45.63 (21.60) | 39.27 (13.50) | 44.05 (19.11) | 62.24 (12.94) | 51.88 (23.17) | 43.23 (20.84) | 48.52 (24.23) | 52.08 (0) |
| Baseline Vigor Score, mean (SD) | 12.21 (5.57) | 12.80 (7.85) | 13.94 (7.11) | 11.25 (6.95) | 13.00 (5.49) | 11.00 (6.06) | 13.79 (5.70 | 15.00 (0) |
| Baseline Ejection Fraction [%], mean (SD) | 51.28 (4.76) | 52.76 (3.55) | 50.79 (4.38) | 49.25 (5.32) | 51.89 (5.68) | 48.00 (2.00) | 51.04 (7.43) | 55.00 (0) |
| Baseline Septal E/e’ Ratio, mean (SD) | 9.35 (4.24) | 8.32 (6.93) | 11.20 (5.97) | 13.76 (7.46) | 9.80 (4.27) | 10.26 (3.13) | 9.41 (5.54) | 0.93 (0) |
| Baseline Total Distance Walked: 6 min Walk Test [m], mean (SD) | 237.85 (131.05) | 166.78 (14.67) | 265.58 (135.96) | 248.20 (211.14) | 322.69 (124.18) | 164.35 (165.96) | 247.87 (150.96) | 438.30 (0) |
| Baseline BNP [pg/ml], mean (SD) | 157.09 (155.27) | 375.80 (462.43) | 152.48 (141.52) | 208.75 (59.53) | 182.51 (211.23) | 613.75 (407.42) | 232.00 (388.28) | 55.00 (0) |
| Baseline lactate [mmol/L], mean (SD) | 2.72 (1.59) | 3.57 (1.29) | 2.34 (1.12) | 2.64 (1.81) | 2.58 (1.04) | 1.95 (0.92) | 2.45 (1.13) | 1.93 (0) |
| Baseline ATP [RLU], mean (SD) | 3,383.24 (954.03) | 3,319.00 (938.38) | 3,312.18 (915.98) | 3,027.00 (478.81) | 3,222.63 (1,040.44) | 3,031.00 (272.74) | 3,332.87 (844.33) | 2,903.00 (0) |
| Baseline lactate/ATP [mmol/L(*RLU)], mean (SD) | 8.58×10−4 (5.53×10−4) | 1.06×10−3 (9.03×10−5) | 7.29×10−4 (3.36×10−4) | 8.72×10−4 (5.44×10−4) | 8.76×10−4 (4.05×10−4) | 6.55×10−4 (3.52×10−4) | 7.93×10−4 (4.03×10−4) | 6.65×10−4 (0) |